Literature DB >> 422228

Isolation and characterization of the third component of rat complement.

M R Daha, M Stuffers-Heiman, A Kijlstra, L A van Es.   

Abstract

The third component of complement from rat plasma was isolated by precipitation with polyethyleneglycol in the presence of benzamidine, followed by chromatography of the precipitate on CM-cellulose, hydroxyapatite, and QAE A50-Sephadex, and gel-filtration on Sephadex G-200 superfine. C3 was isolated in its native form, as assessed by its specific functional activity and its immunoelectrophoretic mobility. The recovery of C3 was between 18 and 26%, and the final material was homogenous on SDS-PAGE analysis. Rat C3 has an apparent molecular weight of 187,000 and it is composed of two non-identical disulphide linked polypeptide chains of 123,000 and 76,000. A monospecific antiserum against rat C3 was produced by immunization of rabbits with purified C3. Zymosan treatment of rat serum resulted in cleavage of C3 and in the appearance of component with a greater mobility during immunoelectrophoresis. The plasma concentration of rat C3 in Wistar rats was 581 +/- 49 microgram/ml (mean +/- 1 S.D.). Interaction of highly purified rat C3 with purified human components B, D, and P resulted in the formation of a C3 convertase suggesting compatibility between human and rat C3.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 422228      PMCID: PMC1457380     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  12 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

Authors:  L G Hunsicker; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

3.  C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

4.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

5.  Isolation and study of murine C3.

Authors:  M B Pepys; A C Dash; A H Fielder; D D Mirjah
Journal:  Immunology       Date:  1977-10       Impact factor: 7.397

6.  Incompatibility between C3b and B of guinea-pig and man and its influence on the titration of the alternative pathway factors D and B in these two species.

Authors:  V Brade; L Dieminger; G Schmidt; W Vogt
Journal:  Immunology       Date:  1976-02       Impact factor: 7.397

7.  Initiation of C3 cleavage in the alternative complement pathway.

Authors:  D T Fearon; K F Austen
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

8.  Isolation of the third component of mouse complement.

Authors:  M I Gyöngyössy; S N Assimeth
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

View more
  5 in total

1.  Characterization of the third component of pig complement and its utilization in a C3b receptor study.

Authors:  J Zídková; V Vĕtvicka; P Rossmann; V Dlabac; J Stránsky
Journal:  Experientia       Date:  1984-09-15

2.  Biosynthesis of the third component of complement in rat liver epithelial cell lines and its stimulation by effector molecules from cultured human mononuclear cells.

Authors:  M Guiguet; M F Exilie Frigere; M C Dethieux; Y Bidan; G Mack
Journal:  In Vitro Cell Dev Biol       Date:  1987-12

3.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

4.  Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis.

Authors:  M H De Baets; J Verschuuren; M R Daha; P J van Breda Vriesman
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

5.  Localization of the membrane attack complex (MAC) in experimental immune complex glomerulonephritis.

Authors:  D Koffler; G Biesecker; B Noble; G A Andres; A Martinez-Hernandez
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.